compositions and dosage forms for administering abusable substances are disclosed which have a reduced potential for abuse without diminishing the therapeutic or beneficial effects of the abusable substance. Topical compositions for application to the skin or mucosa contain the abusable substance in a form which is permeable to the skin or mucosa to which it is to be applied and an antagonist for the abusable substance is present in the composition in an abuse negating amount and in a form that is impermeable to the skin or mucosa to which the composition is to be applied. Controlled release dosage forms which release the abusable substance from a drug reservoir composition confined behind a release rate controlling barrier have the abusable substance and its antagonist in the drug reservoir. The abusable substance is present in a form that is releasable from the dosage form and the antagonist is present in an abuse negating amount in a form that is not releasable from the dosage form. Thus the compositions and dosage forms of this invention permit the therapeutic use, at substantially full potency, of an abusable substance when use as prescribed but reduce the abuse potential of the compositions and dosage forms by other routes of administration. Preferred embodiments of the invention utilize fentanyl as the abusable substance and naltrexone as the antagonist in a transdermal dosage form.

Patent
   5236714
Priority
Nov 01 1988
Filed
Nov 01 1988
Issued
Aug 17 1993
Expiry
Aug 17 2010
Assg.orig
Entity
Large
193
13
all paid
2. A method for administering an abusable substance to the body from a dosage form having a reduced potential for abuse comprising:
a) placing a dosage form containing an amount of an abusable substance and an abuse negating amount of at least one antagonist for said abusable substance in abusable substance delivering relationship to the body;
b) delivering said abusable substance to the body from said dosage form; and
c) retaining said antagonist within said dosage form.
3. A composition of matter for the administration of an abusable substance by application of the composition to the skin or mucosa, said composition having a reduced potential for abuse and comprising a mixture of:
a) an amount of an abusable substance in a form that is permeable to the skin or mucosa to which it is intended to be applied; and
b) an abuse negating amount of at least one antagonist for said abusable substance in a form that is impermeable to the skin or mucosa to which it is to be applied.
1. A method for administering an abusable substance to the skin or mucosa to produce a predetermined beneficial effect which comprises:
a) contacting the skin or mucose with a composition comprising a mixture of:
i) an amount of an abusable substance in a form that is permeable to the skin or mucosa to which it is intended to be applied; and
ii) an abuse negating amount of at least one antagonist for said abusable substance in a form that is impermeable to the skin or mucosa to which it is to be applied; and
b) maintaining said composition on the skin or mucosa for a period of time at least sufficient for the abusable substance to produce the beneficial effect.
7. A dosage form for administering an abusable substance to the body, said dosage form having a reduced potential for abuse and comprising, in combination:
a) abusable substance releasing means through which said abusable substance is released to the body; and
b) a drug reservoir separated from the body by said releasing means, said reservoir comprising a mixture of said abusable substance and an abuse negating amount of at least one antagonist for said abusable substance:
i) said abusable substance being present in said reservoir in a form that is releasable to the body through said releasing means; and
ii) said antagonist being present in said reservoir in a form that is not releasable through said releasing means.
16. A method for administering an abusable substance selected from the group consisting of fentanyl, sufentanil, carfentanil, lofentanil, alfentanil, hydromorphone, exycodone, propoxyphene, pentazocine, methadone, tilidine, butorphanol, buprenorphine, levorphanol, codeine, oxymorphone, meperidine, dihydrocodeinone and cocaine to the body from a dosage form having a reduced potential for abuse comprising:
a) placing a dosage form containing an amount of an abusable substance and an abuse negating amount of at least one antagonist for said abusable substance in abusable substance delivering relationship to the body;
b) delivering said abusable substance to the body from said dosage form; and
c) retaining said antagonist within said dosage form.
19. A composition of matter for the administration of an abusable substance selected from the group consisting of fentanyl, sufentanil, carfentanil, lofentanil, alfentanil, hydromorphone, oxycodone, propoxyphene, pentazocine, methadone, tilidine, butorphanol, buprenorphine, levorphanol, codeine, oxymorphone, meperidine, dihydrocodeinone and cocaine by application of the composition to the skin or mucosa, said composition having a reduced potential for abuse and comprising a mixture of:
a) an amount of an abusable substance in a form that is permeable to the skin or mucosa to which it is intended to be applied; and
b) an abuse negating amount of at least one antagonist for said abusable substance in a form that is impermeable to the skin or mucosa to which it is applied.
26. A dosage form for the administration of fentanyl through the skin or mucosa, said dosage form having a reduced potential for abuse, comprising, in combination:
a) fentanyl releasing means through which fentanyl is released to the skin or mucosa;
b) reservoir means separated from the skin or mucosa by said releasing means, said reservoir comprising a mixture of fentanyl and an abuse negating amount of at least one antagonist for fentanyl:
(i) fentanyl being present in said reservoir in a form that is releasable to the skin or mucosa through said releasing means; and
(ii) antagonist being present in said reservoir in a form that is not releasable through said releasing means; and
c) means for maintaining said reservoir in abusable substance releasing relationship to the skin or mucosa.
10. A dosage form for the administration of an abusable substance through the skin or mucosa, said dosage form having a reduced potential for abuse and comprising:
a) abusable substance releasing means through which said abusable substance is released to the skin or mucosa;
b) a drug reservoir separated from the skin or mucosa by said releasing means, said reservoir comprising a mixture of said abusable substance and an abuse negating amount of at least one antagonist for said abusable substance:
i) said abusable substance being present in said reservoir in a form that is releasable to the skin through said releasing means; and
ii) said antagonist being present in said reservoir in a form that is not releasable through said releasing means; and
c) means for maintaining said reservoir in abusable substance releasing relationship to the skin or mucosa.
13. A method for administering an abusable substance selected from the group consisting of fentanyl, sufentanil, carfentanil, lofentanil, alfentanil, hydromorphone, oxycodone, propoxyphene, pentazocine, methadone, tilidine, butorphanol, buprenorphine, levorphanol, codeine, oxymorphone, meperidine, dihydrocodeinone and cocaine to the skin or mucosa to produce a predetermined beneficial effect which comprises:
a) contacting the skin or mucosa with a composition comprising a mixture of:
(i) an amount of said abusable substance in a form that is permeable to the skin or mucosa to which is intended to be applied; and
(ii) an abuse negating amount of at least one antagonist for said abusable substance in a form that is impermeable to the skin or mucosa to which it is to be applied; and
b) maintaining said composition on the skin or mucosa for a period of time at least sufficient to produce the beneficial effect.
20. A dosage form for administering an abusable substance selected from the group consisting of fentanyl, sufentanil, carfentanil, lofentanil, alfentanil, hydromorphone, oxycodone, propoxyphene, pentazocine, methadone, tilidine, butorphanol, buprenorphine, levorphanol, codeine, oxymorphone, meperidine, dihydrocodeinone and cocaine to the body, said dosage form having a reduced potential for abuse and comprising, in combination:
a) abusable substance releasing means through which said abusable substance is release to body;
b) reservoir means separated from the body by said releasing means, said reservoir means comprising a mixture of said abusable substance and an abuse negating amount of at least one antagonist for said abusable substance;
(i) said abusable substance being present in said reservoir means in a form that is releasable to the body through said releasing means; and
(ii) said antagonist being present in said reservoir means in a form that is not releasable through said releasing means.
23. A dosage form for the administration of an abusable substance selected from the group consisting of fentanyl, sufentanil, carfentanil, lofentanil, alfentanil, hydromorphone, oxycodone, propoxyphene, pentazocine, methadone, tilidine, butorphanol, buprenorphine, levorphanol, codeine, oxymorphone, meperidine, dihydrocodeinone and cocaine through the skin or mucosa, said dosage form having a reduced potential for abuse and comprising:
a) abusable substance releasing means through which said abusable substance is released to the skin or mucosa;
b) reservoir means separated from the skin or mucosa by said releasing means, said reservoir means comprising a mixture of said abusable substance and an abuse negating amount of at least one antagonist for said abusable substance;
(i) said abusable substance being present in said reservoir means in a form that is releasable to the skin through said releasing means;
(ii) said antagonist being present in said reservoir in a form that is not releasable through said releasing means; and
c) means for maintaining said reservoir in abusable substance releasing relationship to the skin or mucosa.
4. The composition of claim 3 further comprising a pharmaceutically acceptable carrier within which said abusable substance and said antagonist are dispersed.
5. The composition of claim 3 wherein said antagonist is selected from the group of impermeable forms of naloxone, naltrexone, nalbuphine and levallorphan.
6. The composition of claim 3 wherein said antagonist is naltrexone.
8. The dosage form of claim 7 wherein said releasing means comprises a semipermeable material permeable to water and impermeable to said abusable substance and said antagonist and said drug reservoir comprises a water soluble form of said abusable substance and a water insoluble form of said antagonist and said semipermeable material is provided with outlet means for a solution of said abusable substance.
9. The dosage form of claim 7 wherein said releasing means is permeable to said abusable substance and impermeable to said antagonist.
11. The dosage form of claim 10 wherein said releasing means comprises a semipermeable material permeable to water and impermeable to said abusable substance and said antagonist and said drug reservoir comprises a water soluble form of said abusable substance and a water insoluble form of said antagonist and said semipermeable material is provided with outlet means for a solution of said abusable substance.
12. The dosage form of claim 10 wherein said releasing means is permeable to said abusable substance and impermeable to said antagonist.
14. The method of claim 1 wherein said antagonist is selected from the group consisting of naloxone, naltrexone, nalbuphine, nalorphine and levallorphan.
15. The method of claim 13 wherein said antagonist is selected from the group consisting of naloxone, naltrexone, nalbuphine, nalorphine and levallorphan.
17. The method of claim 2 wherein said antagonist is selected from the group consisting of naloxone, naltrexone, nalbuphine, nalorphine and levallorphan.
18. The method of claim 16 wherein said antagonist is selected from the group consisting of naloxone, naltrexone, nalbuphine, nalorphine and levallorphan.
21. The dosage form of claim 7 wherein said antagonist is selected from the group consisting of naloxone, naltrexone, nalbuphine, nalorphine and levallorphan.
22. The dosage form of claim 20 wherein said antagonist is selected from the group consisting of naloxone, naltrexone, nalbuphine, nalorphine and levallorphan.
24. The dosage form of claim 10 wherein said antagonist is selected from the group consisting of naloxone, naltrexone, nalbuphine, nalorphine and levallorphan.
25. The dosage form of claim 23 wherein said antagonist is selected from the group consisting of naloxone, naltrexone, nalbuphine, nalorphine and levallorphan.
27. The dosage form of claim 26 wherein said antagonist is selected from the group consisting of naloxone and naltrexone.
28. The dosage form of claim 27 wherein the releasing means comprises an ethylene vinyl acetate copolymer.
29. The composition of claim 19 wherein said antagonist is selected from the group consisting of naloxone, naltrexone, nalbuphine, nalorphine and levallorphan.

This invention relates to dosage forms of abusable substances having reduced potential for abuse. In particular, the dosage forms of this invention are intended to administer the abusable substance to the body by topical application to the skin or mucosa or to release the abusable substance to the body through a membrane on the dosage form.

The potential for abuse by either oral or parenteral routes of narcotic and other psychoactive drugs is well known. For example, the potential for abuse of the synthetic narcotic drug fentanyl is so high that it has become a major cause of death for anesthesiologists and other hospital workers having access to the drug. In order to prevent abuse of these substances, it has been proposed to provide dosage forms which combine the abusable substance with an amount of an antagonist for the abusable substance sufficient to eliminate the "high" associated with abuse of the substance without eliminating the other therapeutic benefits for which the drugs are intended to be administered. See, for example, U.S. Pat. Nos. 4,457,933, 3,493,657 and 3,773,955 which are incorporated herein by reference.

Many abusable substances are capable of being administered to the body by direct application of the drug to the skin or mucosa, i.e., nasal, vaginal, oral, or rectal mucosa. They can also be delivered to the body from advanced dosage forms such as those described in U.S. Pat. Nos. 4,655,766, 4,588,580, 3,993,073, and 3,845,770 which are incorporated herein by reference. Compositions suitable for topical application to the skin or for forming reservoir compositions in the advanced dosage forms described above could be subject to abuse, and it would clearly be desirable to have such compositions or dosage forms available in a condition in which the abuse potential of the composition or dosage form is reduced without diminishing the therapeutic efficacy of the abusable substance to be administered.

It is, accordingly, an object of this invention to provide a composition of matter for topical application of an abusable substance to the body, which composition has a low potential for abuse.

It is another object of this invention to provide a dosage form for the therapeutic administration of an abusable substance, which dosage form has a low potential for abuse.

It is another object of this invention to provide a transdermal dosage form of an abusable substance having a low potential for abuse.

It is a further object of this invention to provide methods for administering abusable substances to the body from compositions and devices having a low potential for abuse.

These and other objects of the invention will be readily apparent from the following description of the invention with reference to the accompanying drawings wherein:

FIG. 1 is a schematic cross-section of one embodiment of this invention;

FIG. 2 is a schematic cross-section of another embodiment of this invention;

FIG. 3 is a schematic cross-section of another embodiment of this invention; and

FIG. 4 is a schematic cross-section of another embodiment of this invention .

The abuse potential that this invention is intended to reduce is not the abuse potential associated with the illicit, nonprescription or recreational use of the topical composition or dosage form of this invention in the same mode of administration as intended for its therapeutic use. Instead, the abuse potential referred to herein relates to the use of the topical or drug reservoir compositions of this invention by other modes of administration such as the injection or ingestion of a topical composition intended to be applied directly to the skin or the removal of the drug reservoir composition from the dosage form and the injection or ingestion of the drug reservoir composition.

In its broadest aspect, this invention contemplates a composition of matter adapted for topical administration to the skin or mucosa which comprises a mixture, typically in a pharmaceutically acceptable carrier, of an abusable substance in combination with an amount of antagonist for said abusable substance sufficient to substantially negate the pharmacological effect of the abusable substance; the abusable substance being present in said composition in a form which is permeable through the skin or other body membrane to which it is to be applied and the antagonist being present in the composition in a form which is substantially impermeable to the skin or other body membrane to which the topical composition is to be applied.

In another aspect of this invention, a composition containing the abusable substance and an amount of an antagonist therefor sufficient to substantially negate the pharmacological effect of the abusable substance forms the drug reservoir composition of a dosage form in which the drug reservoir composition is confined within and separated from the body surface or fluid to which the abusable substance is to be administered by a barrier through which the abusable substance is released and the antagonist is not released.

Thus, if the dosage form is an osmotically driven dosage form such as described in U.S. Pat. Nos. 4,655,766 of 3,845,770, the abusable substance could be present in the drug reservoir in a soluble, osmotically active form and the antagonist could be present in an insoluble, osmotically inactive form. If the dosage form operates on principles of diffusion, such as shown in U.S. Pat. Nos. 3,993,073 and 4,588,580, the abusable substance could be present in the drug reservoir in a form that would be permeable to the material forming the barrier and the antagonist would be present in a form that would be impermeable to the material forming the barrier.

Drugs having a potential for abuse include natural and synthetic narcotics and other psychoactive substances. Representative of such substances are, without limitation, analgetic agents such as fentanyl, sufentanil, carfentanil, lofentanil, alfentanil, hydromorphone, oxycodone, propoxyphene, pentazocine, methadone, tilidine, butorphanol, buprenorphine, levorphanol, codeine, oxymorphone, meperidine, dihydrocodeinone and cocaine.

As used herein, an antagonist for an abusable substance is a compound or composition which acts on the recipient to prevent or substantially diminish the pharmacological effects of the abusable substance or to substantially delay their manifestation. Thus, with respect to natural and synthetic narcotic agents, typical antagonists include, without limitation, naloxone, naltrexone, nalbuphine, nalorphine and levallorphan.

The amount of antagonist required to prevent the occurrence of the pharmacological effect of an abusable substance will vary from substance to substance and antagonist to antagonist but can be readily determined from information available to the art regarding the pharmacokinetics and pharmacodynamics of the particular abusable substance and the particular antagonist. In the event of abuse of the unused reservoir compositions, in those circumstances in which the abusable substance has a significantly longer half-life in the body than the antagonist, the antagonist will prevent the occurrence of the pharmacological effect for a substantial period of time but may thereafter allow some pharmacological effect to be manifested.

This is because pharmacologically effective amounts of the abusable substance may linger in the body after the levels of the antagonist have been reduced below the effective level. In this circumstance the abuse potential of the dosage form will still be reduced because of the substantial delay between the ingestion or injection of the composition of this invention and the onset of the abuse inducing pharmacological effects. If the substance being abused does not promptly produce the effects for which it is being abused, its abuse potential will obviously be substantially reduced. Delays in the onset of the abuse inducing effects of as little as 15 minutes to 1/2 hour can significantly reduce the abuse potential, and compositions according to this invention can easily produce delays significantly longer than that.

Certain antagonists, such as naltrexone, are effective both orally and parenterally although the parenteral half-life may be much shorter than the oral half-life. Other antagonists, such as naloxone, are much more effective parenterally than orally.

Also, most narcotics are significantly more potent when administered parenterally than orally. Fentanyl, for example, is only about 1/10 as potent on oral, as compared to parenteral, administration. Thus, oral abuse is not a significant problem with fentanyl, and an antagonist such as naloxone that is primarily parenterally active can be used. If, however, an abusable substance is both orally and parenterally active, an antagonist such as naltrexone would be preferred or a mixture of orally active and parenterally active antagonists could be used according to this invention. Further, intravenous abuse generally produces the desired abuse inducing effect more rapidly and with greater intensity than oral abuse and is, for many abusers, the preferred route of administration of an abusable substance. Thus, the use of an orally inactive antagonist can still substantially reduce the potential for abuse of the compositions and dosage forms of this invention.

Accordingly, as used herein, an antagonist is present in the compositions or dosage forms of this invention in an "abuse negating amount" if the amount of antagonist is sufficient, when administered by at least one manner of potential abuse other than the manner by which the composition or dosage form is intended to be administered, to prevent or diminish the occurrence of the pharmacological effects of the abusable substance or to significantly delay the onset of these effects.

As used herein, abusable substances and antagonists are considered to be permeable through the skin or mucosa if present in the composition or dosage form as a chemical entity which is capable of producing its intended pharmacological effect when topically applied to the skin or mucosa either by direct application of the composition to the skin or by application of a dosage form containing the composition. Similarly, abusable substances and antagonists are considered to be impermeable through skin or mucosa if present in the dosage form as a chemical entity which is incapable of producing its intended pharmacological effect when topically applied at the administration site.

For example, as pointed out in U.S. Pat. No. 4,588,580, fentanyl and its derivatives are permeable through the skin as the base form of the drug and are impermeable through the skin in ionic form such as the commercially available fentanyl citrate, for example. Antagonists such as naloxone, naltrexone and nalbuphine, as shown in U.S. Pat. No. 4,573,995 which is incorporated herein by reference, are impermeable to the skin in the absence of an appropriate permeation enhancer.

Similarly, abusable substances and antagonists are considered to be permeable to the barrier forming a dosage form if the rate of permeation of the abusable substance or antagonist through the barrier is sufficient to permit the abusable substance or the antagonist to produce its desired systemic effect from the site of administration and impermeable to the barrier if the rate of permeation is insufficient to permit the abusable substance or antagonist to produce its desired effect at the site of administration.

Referring now to FIG. 1, a composition 1 for topical application to the skin or mucosa according to this invention comprises a pharmaceutically acceptable carrier 2 having uniformly dispersed therethrough an amount of an abusable substance 3 in a skin or mucosa permeable form and an abuse negating amount of an antagonist 4 for said abusable substance in a skin or mucosa impermeable form. The composition 1 may be applied directly onto the skin or mucosa from a container for the same, such as a bottle or tube, and subsequently covered, if desired, with a protective overlay. It is preferable, however, to quantify the dose and the area of application by placing the composition in an impermeable container 5 of the correct size to provide a unit dose which may be held on the skin by adhesive means 6 or other appropriate fastening means.

In operation the composition of FIG. 1 would administer the abusable substance through the skin or mucosa to produce the intended therapeutic effect, and the antagonist would not significantly affect or diminish the therapeutic effect of the abusable substance. If, on the other hand, an attempt were made to abuse the composition 1 by administration through some other portal, such as orally or intravenously, the antagonist would produce its antagonistic effect and prevent the occurrence of the abuse inducing effect.

In addition to the abusable substance and the antagonist, composition 1 may also contain a permeation enhancer for the abusable substance which should not significantly enhance the permeability of the antagonist, thickeners and other additives, all as known to the art. The composition 1 can be in the form of an ointment, cream, gel, paste, solution or lotion, for example.

Referring now to FIG. 2, a dosage form 10 for administering an abusable substance to the skin or mucosa according to this invention is shown in which the reservoir composition has a reduced potential for abuse. The dosage form 10 comprises a drug reservoir composition 11 typically in the form of a gel or polymeric carrier 12 having uniformly dispersed therethrough an abusable therapeutic agent 13 and an abuse negating amount of an antagonist therefor 14. The composition 11 is preferably disposed between an impermeable backing 15, an abusable substance releasing means such as release rate controlling membrane 16 and an abusable substance permeable adhesive 17, all as is known to the art. An abusable substance and antagonist impermeable release liner 18 is applied to the adhesive layer and is removed prior to use. Suitable materials for use in manufacturing the various layers are described in the above-identified patents.

In this embodiment of the invention the abusable substance 13 is present in the reservoir composition in a form which is permeable through the rate controlling membrane 16. The antagonist 14 is present in a form which is not permeable through either the rate controlling membrane 16, the adhesive 17 or the skin.

In operation, the dosage form 10 would administer the abusable substance through the skin at the rate intended for therapeutic effect, and the antagonist would not significantly affect or diminish the therapeutic effect of the abusable substance. If, on the other hand, an attempt were made to abuse dosage form 10 by administration of drug reservoir composition 11 through some other portal, such as orally or intravenously, the antagonist would produce its antagonistic effect and prevent the occurrence of the abuse inducing effect.

Referring now to FIG. 3, a dosage form 20 is shown for orally administering an orally active abusable substance. Dosage form 20 comprises a drug reservoir composition 21 comprising a carrier having uniformly dispersed therethrough an abusable substance 22 and an abuse negating amount of at least one antagonist 23 for said abusable substance, said composition being enclosed within abusable substance releasing means 24. The abusable substance is present in the composition in a form that is permeable through means 24, and the antagonist is present in a form that is impermeable to means 24. If it is desired to prevent both oral and parenteral abuse of the reservoir composition, antagonist 23 should be either an orally or parenterally active antagonist or a mixture of orally and parenterally active antagonists.

In operation, the dosage form 20 would be administered orally. The abusable substance would be delivered through the releasing means 24 to the gastrointestinal tract gradually at the controlled rate intended for therapeutic effect and the antagonist would not significantly affect or diminish the therapeutic effect of the abusable substance. If, on the other hand, an attempt were made to abuse the composition 21, in order to rapidly obtain the abuse inducing effect, by removing it from the dosage form 20 and ingesting the composition or administering it through some other portal, such as intravenously, the antagonist would produce its antagonistic effect and prevent the occurrence of the abuse inducing effect.

Referring now to FIG. 4, another embodiment of this invention is shown in which the dosage form 30 operates on osmotic principals. In this embodiment, the dosage form 30 comprises a drug reservoir composition 31 comprising an osmotically active abusable substance 32 dispersed within an abuse negating amount of at least one osmotically inactive antagonist 33 for said abusable substance enclosed within a semipermeable housing 34. Housing 34 is permeable to water, impermeable to the abusable substance and the antagonist and is provided with an outlet 35 through which the abusable substance solution formed within the housing can be osmotically discharged. The abusable substance is present in the drug reservoir composition in a soluble, osmotically active form and the antagonist is present in an insoluble, osmotically inactive form.

In operation, the dosage form 30 would be orally administered. When the dosage form is in contact with body fluids, water will pass through the semipermeable housing 34 by osmosis, forming a solution of the abusable substance 32 which will be pumped out of the outlet 35 at the same rate that water passes into the dosage form 30. The antagonist, being insoluble, will not enter into solution and will remain within housing 34. Thus, the abusable substance will be administered at the rate intended for therapeutic effect, and the antagonist would not significantly affect or diminish the therapeutic effect of the abusable substance. If, on the other hand, an attempt were made to abuse the composition 31 by removing it from the dosage form 30 and ingesting the composition or administering it through some other portal, such as intravenously, the antagonist would produce its antagonistic effect and prevent the occurrence of the abuse inducing effect.

Having thus generally described our invention, the following examples illustrate various embodiments of our invention.

Aqueous gels for topical application to the skin to administer the abusable substance, fentanyl, transdermally are prepared from a mixture having the following formulation:

______________________________________
Component % by weight
______________________________________
Ethanol 22.1
Hydroxyethyl 1.9
Cellulose
Fentanyl base 1.0
Naloxone base 1.0
or
Naltrexone HCl 20.0
Water Balance
______________________________________

The gels of this example contain abuse negating amounts of the antagonists and can be topically applied to the skin to administer fentanyl to the body without administering any therapeutically significant amount of the antagonists. Ethanol is a selective skin permeation enhancer in that it significantly increases the flux of fentanyl through skin without producing any therapeutically significant effect on the skin flux of the antagonists. The parenteral half-lives of naloxone and naltrexone are significantly shorter than the half-life of fentanyl, and naloxone and fentanyl are relatively inactive on oral administration. Thus, the gels containing naloxone or naltrexone will significantly delay the onset of the abuse inducing effects of the fentanyl in the event of I.V. abuse of the compositions of Example 1. The gels containing naltrexone HCl will also be more effective than the gel containing naloxone in preventing the oral abuse of the compositions of Example 1.

Transdermal delivery devices having a drug releasing area of approximately 10 cm2 are prepared by pouching, in a rotary heat sealing machine, the compositions of Example 1 between an impermeable backing formed from an aluminized polyester/ethylene vinyl acetate copolymer (EVA) film (Scotchpak 1018 available from 3M Corporation) and a multi-laminate film comprising the rate controlling membrane, 2 mil EVA (9% VA), 1.8 mil of an amine resistant silicone adhesive (Dow Corning X7920) and a fluorocarbon coated polyethylene terephthalate release liner

(Scotchpak 1022) at a gel loading of approximately 15 mg/cm2. The steady state release rate of fentanyl, naloxone and naltrexone from such systems into an aqueous bath as determined at 32°C will be approximately as follows:

Fentanyl: 4.0 mcg/cm2 /hr

Naloxone base: 0.15 mcg/cm2 /hr

Naltrexone HCl: 0.2 mcg/cm2 /hr

The rate of release of the fentanyl is sufficient to produce therapeutic effects upon application of the dosage forms to the body and maintenance of the devices in place for 24 hours, for example. The rates of release of the antagonists, however, are insufficient to produce any significant reduction of the beneficial effect of the fentanyl when administered transdermally. Even if the antagonists were released from the dosage form at significantly higher rates, they would not be antagonistically effective because neither is permeable to the skin in the absence of a permeation enhancer. Ethanol is not a permeation enhancer for either naloxone or naltrexone HCl. However, as with the compositions of Example 1, the unused and used reservoir compositions will have reduced potential for abuse should the reservoir compositions be removed from the device and used in an abusive manner as described above.

Although this invention has been described with respect to various embodiments thereof it should not be construed as being limited thereto. Various modification can be made to the subject matter disclosed herein within departing from the scope of this invention which is limited only by the following claims wherein:

Goetz, Victor, Lee, Eun S.

Patent Priority Assignee Title
10010543, Dec 23 2014 CLEXIO BIOSCIENCES LTD Transdermal dosage form
10064828, Dec 23 2005 Intellipharmaceutics Corp Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
10071089, Jul 23 2013 EURO-CELTIQUE S A Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
10092519, Apr 21 2003 PURDUE PHARMA L.P. Pharmaceutical products
10092559, Sep 12 2014 SOCIETAL CDMO GAINESVILLE, LLC Abuse resistant pharmaceutical compositions
10213586, Jan 28 2015 Morningside Venture Investments Limited Drug delivery methods and systems
10232156, Jan 28 2015 Morningside Venture Investments Limited Drug delivery methods and systems
10245228, Jan 06 2006 Vertical Pharmaceuticals, LLC Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
10258235, Feb 28 2005 PURDUE PHARMA L P Method and device for the assessment of bowel function
10258738, Sep 13 2004 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, AIDs, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
10258778, Sep 13 2004 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
10342762, Jan 06 2006 Vertical Pharmaceuticals, LLC Small-volume oral transmucosal dosage forms
10350173, Feb 08 2000 PURDUE PHARMA L.P. Tamper resistant oral opioid agonist formulations
10391346, Jan 23 2004 VERDE ENVIRONMENTAL TECHNOLOGIES, INC Abuse potential reduction in abusable substance dosage form
10406154, Dec 23 2014 CLEXIO BIOSCIENCES LTD Transdermal dosage form
10406394, Jan 23 2004 VERDE ENVIRONMENTAL TECHNOLOGIES, INC Abuse potential reduction in abusable substance dosage form
10413768, Jan 23 2004 VERDE ENVIRONMENTAL TECHNOLOGIES, INC Abuse potential reduction in abusable substance dosage form
10420762, Apr 05 2002 PURDUE PHARMA L.P. Pharmaceutical preparation containing oxycodone and naloxone
10507180, Jan 06 2006 Vertical Pharmaceuticals, LLC Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
10568845, Aug 24 2001 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system with fentanyl or related substances
10583093, Aug 24 2001 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system with fentanyl or related substances
10588865, Feb 08 2000 PURDUE PHARMA L.P. Tamper resistant oral opioid agonist formulations
10624858, Aug 23 2004 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
10632205, May 12 2006 Intellipharmaceutics Corp Pharmaceutical composition having reduced abuse potential
10653686, Jul 06 2011 TYLER MEDICAL RESEARCH, LLC Compositions and methods for treatment of symptoms in parkinson's disease patients
10679516, Mar 12 2015 Morningside Venture Investments Limited Craving input and support system
10709881, Jan 06 2006 AcelRx Pharmaceuticals, Inc. Apparatus for administering small volume oral transmucosal dosage forms
10716764, Oct 27 2003 Morningside Venture Investments Limited Transdermal drug delivery method and system
10729686, Feb 28 2008 LIBERO PHARMA LIMITED Pharmaceutical compositions
10940122, Aug 24 2001 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system with fentanyl or related substances
10960000, Sep 12 2014 SOCIETAL CDMO GAINESVILLE, LLC Abuse resistant pharmaceutical compositions
10960077, May 12 2006 Intellipharmaceutics Corp Abuse and alcohol resistant drug composition
11285306, Jan 06 2017 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
11305144, Jan 23 2004 Verde Environmental Technologies, Inc. Abuse potential reduction in abusable substance dosage form
11389844, Mar 20 2018 VERDE ENVIRONMENTAL TECHNOLOGIES, INC Blister pack disposal system
11400266, Jan 28 2015 Morningside Venture Investments Limited Drug delivery methods and systems
11471424, Sep 13 2004 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
11596779, May 29 2018 CHRONO THERAPEUTICS INC Drug delivery methods and systems
11607407, Apr 13 2010 RELMADA THERAPEUTICS, INC Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use
11883865, Mar 20 2018 VERDE ENVIRONMENTAL TECHNOLOGIES, INC Blister pack disposal system
5776665, Dec 22 1994 Eastman Kodak Company Photographic processing composition and method using organic catalyst for peroxide bleaching agent
6228863, Dec 22 1997 PURDUE PHARMA L P Method of preventing abuse of opioid dosage forms
6277384, Dec 22 1997 PURDUE PHARMA L P Opioid agonist/antagonist combinations
6375957, Dec 22 1997 PURDUE PHARMA L P Opioid agonist/opioid antagonist/acetaminophen combinations
6475494, Dec 22 1997 PURDUE PHARMA L P Opioid agonist/antagonist combinations
6627635, Dec 22 1997 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
6696066, Dec 22 1997 PURDUE PHARMA L P Opioid agonist/antagonist combinations
6696088, Feb 08 2000 PURDUE PHARMA L P Tamper-resistant oral opioid agonist formulations
6716449, Feb 08 2000 PURDUE PHARMA L P Controlled-release compositions containing opioid agonist and antagonist
7011843, Oct 01 1997 LTS Lohmann-Therapie Systeme AG Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
7172767, Dec 22 1997 PURDUE PHARMA L P Opioid agonist / antagonist combinations
7182955, Apr 30 2003 KINDEVA DRUG DELIVERY L P Abuse-resistant transdermal dosage form
7226619, Sep 07 2004 PHARMORX INC Material for controlling diversion of medications
7230005, Mar 13 2003 CONTROLLED CHEMICALS, INC Compounds and methods for lowering the abuse potential and extending the duration of action of a drug
7276250, Jul 06 2001 ENDO USA, INC Sustained release formulations of oxymorphone
7384653, Sep 23 2004 PURDUE PHARMA L P Oral dosage form comprising a therapeutic agent and an adverse-effect agent
7419686, Dec 22 1997 PURDUE PHARMA L.P. Opioid agonist/antagonist combinations
7658939, Feb 08 2000 PURDUE PHARMA L P Tamper-resistant oral opioid agonist formulations
7682632, Nov 04 2003 PURDUE PHARMA L P Tamper-resistant oral opioid agonist formulations
7682633, Jun 19 2006 Alpharma Pharmaceuticals, LLC Pharmaceutical composition
7682634, Jun 19 2006 Alpharma Pharmaceuticals, LLC Pharmaceutical compositions
7718192, Nov 04 2003 PURDUE PHARMA L P Tamper-resistant oral opioid agonist formulations
7736665, May 31 2002 FEDSON, INC Implantable polymeric device for sustained release of buprenorphine
7740879, Jan 17 2006 HARROGATE HOLDINGS NEW JERSEY INC Abuse resistant transdermal drug delivery patch
7749542, Dec 22 1997 Purdue Pharma LP Opioid agonist/antagonist combinations
7815934, Sep 20 2002 Alpharma Pharmaceuticals, LLC Sequestering subunit and related compositions and methods
7827983, Dec 20 2004 Hewlett-Packard Development Company, L.P. Method for making a pharmaceutically active ingredient abuse-prevention device
7842309, Feb 08 2000 PURDUE PHARMA L P Tamper-resistant oral opioid agonist formulations
7842311, Feb 08 2000 PURDUE PHARMA L P Tamper-resistant oral opioid agonist formulations
7867511, Jan 23 2004 VERDE ENVIRONMENTAL TECHNOLOGIES, INC Abuse potential reduction in abusable substance dosage form
7914818, Aug 06 2001 PURDUE PHARMA L P Opioid agonist formulations with releasable and sequestered antagonist
7943173, Jul 18 2001 PURDUE PHARMA L P Pharmaceutical combinations of oxycodone and naloxone
8105631, Dec 22 1997 PURDUE PHARMA L.P. Opioid agonist/antagonist combinations
8158156, Jun 19 2007 Alpharma Pharmaceuticals, LLC Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
8182836, Apr 08 2003 Elite Laboratories, Inc. Abuse-resistant oral dosage forms and method of use thereof
8202535, Jan 06 2006 Vertical Pharmaceuticals, LLC Small-volume oral transmucosal dosage forms
8216604, Jan 10 2003 BTCP PHARMA, LLC Method of managing or treating pain
8231900, Oct 11 2007 Vertical Pharmaceuticals, LLC Small-volume oral transmucosal dosage
8231901, Aug 06 2001 PURDUE PHARMA L.P. Opioid agonist formulations with releasable and sequestered antagonist
8236351, Feb 08 2000 PURDUE PHARMA L.P. Tamper-resistant oral opioid agonist formulations
8246977, Oct 21 2004 DURECT CORPORATION Transdermal delivery systems
8252319, Oct 21 2004 DURECT CORPORATION Transdermal delivery system for sufentanil
8252320, Oct 21 2004 DURECT CORPORATION Transdermal delivery system for sufentanil
8252328, Jan 06 2006 Vertical Pharmaceuticals, LLC Bioadhesive drug formulations for oral transmucosal delivery
8252329, Jul 03 2007 Vertical Pharmaceuticals, LLC Bioadhesive drug formulations for oral transmucosal delivery
8309122, Jul 06 2001 ENDO OPERATIONS LIMITED Oxymorphone controlled release formulations
8329212, Jan 23 2004 VERDE ENVIRONMENTAL TECHNOLOGIES, INC Abuse potential reduction in abusable substance dosage form
8329216, Jul 06 2001 ENDO OPERATIONS LIMITED Oxymorphone controlled release formulations
8357114, Jan 06 2006 ACELRX PHARMACEUTICALS, INC Drug dispensing device with flexible push rod
8357399, Feb 08 2000 PURDUE PHARMA L.P. Tamper-resistant oral opioid agonist formulations
8394409, Jul 01 2004 Intellipharmaceutics Corp Controlled extended drug release technology
8425933, Apr 08 2003 Elite Laboratories, Inc. Abuse-resistant oral dosage forms and method of use thereof
8440220, Apr 23 2002 DURECT CORPORATION Transdermal analgesic systems with reduced abuse potential
8445010, Jan 23 2004 VERDE ENVIRONMENTAL TECHNOLOGIES, INC Abuse potential reduction in abusable substance dosage form
8465774, Aug 06 2001 PURDUE PHARMA L P Sequestered antagonist formulations
8475837, Jan 23 2004 VERDE ENVIRONMENTAL TECHNOLOGIES, INC Abuse potential reduction in abusable substance dosage form
8499966, Jan 05 2007 ACELRX PHARMACEUTICALS, INC Method of moving a delivery member of a dispensing device for administration of oral transmucosal dosage forms
8518443, Aug 06 2001 Purdue Pharma, L.P. Opioid agonist formulations with releasable and sequestered antagonist
8518925, Jun 08 2004 PURDUE PHARMA L P Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
8535711, Jan 23 2004 VERDE ENVIRONMENTAL TECHNOLOGIES, INC Medication disposal system
8535714, Jan 06 2006 Vertical Pharmaceuticals, LLC Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
8586088, Feb 08 2000 PURDUE PHARMA L.P. Tamper-resistant oral opioid agonist formulations
8603520, Jun 26 2003 INTELLIPHARMACEUTICS CORP. Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
8623418, Dec 17 2007 Alpharma Pharmaceuticals LLC Pharmaceutical composition
8632800, May 13 2005 DURECT CORPORATION Multilayer drug delivery system with barrier against reservoir material flow
8673355, Dec 22 1997 PURDUE PHARMA L.P. Opioid agonist/antagonist combinations
8685443, Sep 20 2002 Alpharma Pharmaceuticals LLC Sequestering subunit and related compositions and methods
8685444, Sep 20 2002 Alpharma Pharmaceuticals LLC Sequestering subunit and related compositions and methods
8703177, Aug 18 2011 BIODELIVERY SCIENCES INTERNATIONAL, INC Abuse-resistant mucoadhesive devices for delivery of buprenorphine
8703186, Apr 08 2003 Elite Laboratories, Inc. Abuse-resistant oral dosage forms and method of use thereof
8747889, Apr 23 2002 DURECT CORPORATION Transdermal analgesic systems with reduced abuse potential
8753308, Jan 06 2006 AcelRx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
8758825, Aug 06 2001 PURDUE PHARMA L.P. Sequestered antagonist formulations
8778382, Apr 30 2003 PURDUE PHARMA L P Tamper resistant transdermal dosage form
8778393, Jan 06 2006 Vertical Pharmaceuticals, LLC Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
8778394, Jan 06 2006 Vertical Pharmaceuticals, LLC Small-volume oral transmucosal dosage forms
8790583, Sep 30 2011 VERDE ENVIRONMENTAL TECHNOLOGIES, INC Transdermal patch disposal system
8790689, Apr 30 2003 PURDUE PHARMA L P Tamper resistant transdermal dosage form
8802139, Jun 26 2003 Intellipharmaceutics Corp Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
8815287, Aug 06 2001 PURDUE PHARMA L.P. Opiod agonist formulations with releasable and sequestered antagonist
8822487, Dec 22 1997 PURDUE PHARMA L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
8846090, Apr 05 2002 PURDUE PHARMA L P Matrix for sustained, invariant and independent release of active compounds
8846091, Apr 05 2002 PURDUE PHARMA L P Matrix for sustained, invariant and independent release of active compounds
8846104, Jun 19 2006 Alpharma Pharmaceuticals LLC Pharmaceutical compositions for the deterrence and/or prevention of abuse
8852623, Mar 31 2003 FEDSON, INC Implantable polymeric device for sustained release of dopamine agonist
8865211, Jan 06 2006 Vertical Pharmaceuticals, LLC Bioadhesive drug formulations for oral transmucosal delivery
8865743, Jan 06 2006 Vertical Pharmaceuticals, LLC Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
8877247, Jun 19 2006 Alpharma Pharmaceuticals LLC Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
8889176, Jan 10 2003 BTCP PHARMA, LLC Method of managing or treating pain
8905964, Jan 05 2007 AcelRx Pharmaceuticals, Inc. Drug storage and dispensing devices and systems comprising the same
8906413, May 12 2003 Supernus Pharmaceuticals, Inc Drug formulations having reduced abuse potential
8932630, Dec 22 1997 Purdue Pharma L.P Opioid agonist/antagonist combinations
8936808, Dec 22 1997 PURDUE PHARMA L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
8936812, Feb 08 2000 PURDUE PHARMA L.P. Tamper-resistant oral opioid agonist formulations
8945592, Nov 21 2008 Vertical Pharmaceuticals, LLC Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
8969369, May 11 2001 PURDUE PHARMA L P Abuse-resistant controlled-release opioid dosage form
8979724, Sep 30 2011 VERDE ENVIRONMENTAL TECHNOLOGIES, INC General medication disposal system
9056051, May 11 2001 PURDUE PHARMA L P Abuse-resistant controlled-release opioid dosage form
9066847, Jan 05 2007 ACELRX PHARMACEUTICALS, INC Storage and dispensing devices for administration of oral transmucosal dosage forms
9078814, Jan 10 2003 BTCP PHARMA, LLC Intranasal spray device containing pharmaceutical composition
9078827, May 12 2006 Intellipharmaceutics Corp Pharmaceutical composition having reduced abuse potential
9084729, May 11 2001 PURDUE PHARMA L P Abuse-resistant controlled-release opioid dosage form
9101625, Aug 30 2006 RHODES PHARMACEUTICALS L P Buprenorphine-wafer for drug substitution therapy
9132096, Sep 12 2014 SOCIETAL CDMO GAINESVILLE, LLC Abuse resistant pharmaceutical compositions
9144551, May 12 2003 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
9149436, Apr 21 2003 PURDUE PHARMA L P Pharmaceutical product comprising a sequestered agent
9161937, May 11 2001 PURDUE PHARMA L.P. Abuse-resistant controlled-release opioid dosage form
9168252, May 11 2001 PURDUE PHARMA L.P. Abuse-resistant controlled-release opioid dosage form
9205082, Dec 22 1997 PURDUE PHARMA L.P. Opioid agonist/antagonist combinations
9271940, Mar 10 2009 PURDUE PHARMA L P Immediate release pharmaceutical compositions comprising oxycodone and naloxone
9278073, Feb 08 2000 PURDUE PHARMA L.P. Tamper-resistant oral opioid agonist formulations
9278163, Mar 31 2003 FEDSON, INC Implantable polymeric device for sustained release of dopamine agonist
9283216, May 11 2001 PURDUE PHARMA L.P. Abuse-resistant controlled-release opioid dosage form
9283221, May 11 2001 PURDUE PHARMA L.P. Abuse-resistant controlled-release opioid dosage form
9289583, Jan 06 2006 ACELRX PHARMACEUTICALS, INC Methods for administering small volume oral transmucosal dosage forms using a dispensing device
9308176, Oct 15 2004 Supernus Pharmaceuticals, Inc Less abusable pharmaceutical preparations
9320710, Jan 06 2006 Vertical Pharmaceuticals, LLC Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
9339856, Sep 30 2011 VERDE ENVIRONMENTAL TECHNOLOGIES, INC Transdermal patch disposal system
9345701, May 11 2001 PURDUE PHARMA L.P. Abuse-resistant controlled-release opioid dosage form
9358230, May 11 2001 PURDUE PHARMA L.P. Abuse-resistant controlled-release opioid dosage form
9370512, Aug 30 2006 RHODES PHARMACEUTICALS L P Buprenorphine-wafer for drug substitution therapy
9452163, Sep 12 2014 SOCIETAL CDMO GAINESVILLE, LLC Abuse resistant pharmaceutical compositions
9456989, Feb 08 2000 PURDUE PHARMA L.P. Tamper-resistant oral opioid agonist formulations
9474750, Dec 22 1997 PURDUE PHARMA L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
9480685, May 11 2001 PURDUE PHARMA L.P. Abuse-resistant controlled-release opioid dosage form
9486451, Sep 12 2014 SOCIETAL CDMO GAINESVILLE, LLC Abuse resistant pharmaceutical compositions
9511066, May 11 2001 PURDUE PHARMA L.P. Abuse-resistant controlled-release opioid dosage form
9522188, Dec 13 2005 BIODELIVERY SCIENCES INTERNATIONAL, INC Abuse resistant transmucosal drug delivery device
9555000, Apr 05 2002 PURDUE PHARMA L.P. Pharmaceutical preparation containing oxycodone and naloxone
9561188, Apr 03 2007 INTELLIPHARMACEUTICS CORPORATION Controlled release delivery device comprising an organosol coat
9597288, Jul 21 2006 BioDelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
9636306, Jun 26 2003 INTELLIPHARMACEUTICS CORP. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
9642850, Feb 24 1997 PURDUE PHARMA L.P. Method of providing sustained analgesia with buprenorphine
9642996, Jan 06 2006 AcelRx Pharmaceuticals, Inc. Methods and apparatus for administering small volume oral transmucosal dosage forms
9655843, Jul 21 2006 BPCR LIMITED PARTNERSHIP Transmucosal delivery devices with enhanced uptake
9655855, Apr 05 2002 PURDUE PHARMA L P Matrix for sustained, invariant and independent release of active compounds
9700552, Feb 28 2008 LIBERO PHARMA LIMITED Pharmaceutical compositions for treatment of addiction
9713611, Sep 12 2014 SOCIETAL CDMO GAINESVILLE, LLC Abuse resistant pharmaceutical compositions
9744129, Jan 06 2006 Vertical Pharmaceuticals, LLC Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
9763931, Aug 30 2006 RHODES PHARMACEUTICALS L P Buprenorphine-wafer for drug substitution therapy
9801828, Feb 08 2000 PURDUE PHARMA L.P. Tamper resistant oral opioid agonist formulations
9814705, Jan 10 2003 BTCP PHARMA, LLC Intranasal spray device containing pharmaceutical composition
9820983, Mar 10 2009 PURDUE PHARMA L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
9861628, Aug 30 2006 RHODES PHARMACEUTICALS L P Buprenorphine-wafer for drug substitution therapy
9901539, Dec 21 2011 BPCR LIMITED PARTNERSHIP Transmucosal drug delivery devices for use in chronic pain relief
9907793, Apr 05 2002 PURDUE PHARMA L.P. Pharmaceutical preparation containing oxycodone and naloxone
9949930, Aug 06 2001 PURDUE PHARMA L.P. Opioid agonist formulations with releasable and sequestered antagonist
ER2251,
ER3470,
ER7928,
RE41408, Feb 24 1997 PURDUE PHARMA L P Method of providing sustained analgesia with buprenorpine
RE41489, Feb 24 1997 PURDUE PHARMA L P Method of providing sustained analgesia with buprenorphine
RE45822, Aug 06 2001 PURDUE PHARMA L.P. Oral dosage form comprising a therapeutic agent and an adverse-effect agent
Patent Priority Assignee Title
3493657,
3773955,
3845770,
3993073, Apr 01 1969 ALZA Corporation Novel drug delivery device
4457933, Nov 24 1978 Bristol-Myers Company Prevention of analgesic abuse
4573995, Oct 09 1984 ALZA Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
4582835, Dec 06 1983 RECKITT BENCKISER HEALTHCARE UK LIMITED Analgesic compositions
4588580, Jul 23 1984 ALZA Corporation Transdermal administration of fentanyl and device therefor
4626539, Aug 10 1984 Bristol-Myers Squibb Pharma Company Trandermal delivery of opioids
4655766, Dec 20 1982 ALZA Corporation Fluid imbibing pump with self-regulating skin patch
EP74105,
EP144243,
EP185472,
///
Executed onAssignorAssigneeConveyanceFrameReelDoc
Oct 28 1988LEE, EUN S ALZA CorporationASSIGNMENT OF ASSIGNORS INTEREST 0049710587 pdf
Oct 28 1988GOETZ, VICTORALZA CorporationASSIGNMENT OF ASSIGNORS INTEREST 0049710587 pdf
Nov 01 1988ALZA Corporation(assignment on the face of the patent)
Date Maintenance Fee Events
Feb 14 1997M183: Payment of Maintenance Fee, 4th Year, Large Entity.
Feb 16 2001M184: Payment of Maintenance Fee, 8th Year, Large Entity.
Feb 20 2001ASPN: Payor Number Assigned.
Mar 13 2001REM: Maintenance Fee Reminder Mailed.
Jan 28 2005M1553: Payment of Maintenance Fee, 12th Year, Large Entity.


Date Maintenance Schedule
Aug 17 19964 years fee payment window open
Feb 17 19976 months grace period start (w surcharge)
Aug 17 1997patent expiry (for year 4)
Aug 17 19992 years to revive unintentionally abandoned end. (for year 4)
Aug 17 20008 years fee payment window open
Feb 17 20016 months grace period start (w surcharge)
Aug 17 2001patent expiry (for year 8)
Aug 17 20032 years to revive unintentionally abandoned end. (for year 8)
Aug 17 200412 years fee payment window open
Feb 17 20056 months grace period start (w surcharge)
Aug 17 2005patent expiry (for year 12)
Aug 17 20072 years to revive unintentionally abandoned end. (for year 12)